PETALING JAYA, Malaysia, June 15, 2023 /PRNewswire/ -- European Wellness Biomedical Group (EW Group), announced its partnership with HK VJM Ltd (representing Sinopharm Cloud Health Technology (Guandong) Co. and Sinopharm Traditional Chinese Medicine (Foshan) Co.) and NCL Solutions Sdn Bhd on April 15, 2023 at One World Hotel.
April 13 (Reuters) - Pfizer (PFE.N) said on Thursday it has signed a strategic cooperation agreement with China's Sinopharm Group (1099.HK), and plans to seek approval to market 12 innovative drugs in China through 2025.
More than 30 years after GE HealthCare first joined forces with Sinopharm, China's state-run drugmaker, the partners are renewing their vows.
BEIJING, Jan 20 (Reuters) - Sinopharm (1099.HK) said on Friday its biotech unit has received regulatory approval for clinical trials of its mRNA COVID-19 vaccine targeting the Omicron variant.
Vaxxinity’s next-gen COVID-19 booster candidate has hit its safety targets in a head-to-head phase 3 trial.
Chinese drugmaker Sinopharm said on Monday it has obtained approval to conduct clinical trials of an inhaled monoclonal antibody against the novel coronavirus, a potentially significant weapon against the dominant Omicron variant.
A month ago, Zhejiang Huahai revealed a five-year deal to produce and sell Pfizer’s COVID-19 oral antiviral Paxlovid exclusively in China.
Pfizer coronavirus vaccine has not arrived in Kyrgyzstan yet. The exact date of shipment and amount of doses is unknown yet, National Immunization Center said.
Sinopharm is considering a $1 billion-plus deal to snap up China-based BBI Life Sciences, unnamed sources told Bloomberg. The company has reportedly been in talks with the Wang family, who founded BBI back in 2013.
China National Pharmaceutical Group Co. is among suitors exploring a potential acquisition of BBI Life Sciences Corp., in a deal that could value the Shanghai-based DNA synthesis products supplier at more than $1 billion, according to people familiar with the matter.